Study Finds Some Elite Controllers Indistinguishable From HIV-negative Persons Print E-mail
Wednesday, 22 December 2010 12:46
In an abstract published online ahead of print today in the Journal of Virology, International HIV Controller Study collaborators characterized genetic signatures in the CD4 T-cells of an "unselected" cohort of elite controllers to further elucidate underlying immunological and virological mechanisms of HIV-1 control. Genetic profiles of the majority of elite controllers were similiar to patients on antiretroviral therapy, although different from HIV-1 negative persons. However, in a smaller proportion of elite controllers, an alternative genetic pattern was observed that was indistinguishable from that of HIV-1 negative persons, and different from individuals on highly active antiretroviral medications. Significantly higher CD4 T-cell counts and smaller levels of HIV-1 specific CD8+ T-cell responses were measured in this sub-group of elite controllers. who did not significantly differ from other elite controllers in respect to viral loads and HLA class I alleles. This study team concludes that the data identify a "specific subgroup of elite controllers whose immunological and gene expression characteristics approximate those of HIV-1 negative persons."
Abstract Accessed 12/22/10, at:     Digg This!     Facebook     Google     Reddit     Stumble It!
Last Updated ( Wednesday, 12 January 2011 22:36 )

Please Donate!

Please make a tax deductible donation to Zephyr LTNP Foundation, a 501(c)(3) entity via Paypal. No Paypal account required.

CROI 2011

  • Wednesday 9th March 2011
    This is our final bulletin from CROI 2011. We hope you have found our news coverage useful. You can find all our coverage at, including the news reports and bulletins.We are always looking for ways of improving and developing our resources – so if you have any comments that you would like
  • Thursday 3rd March 2011
    There is increasing evidence of the transmission of HIV strains with resistance to anti-HIV drugs in low- and middle-income countries. Research in eleven sub-Saharan African countries showed that the chances of detecting transmitted resistance increased by over a third each year that a country had been scaling up HIV treatment. A separate study involving people recently diagnosed
  • Wednesday 2nd March 2011
    A new type of anti-HIV drug that targets the first step in HIV’s entry into cells has done well in a Phase IIa study. Currently known as BMS-663068, the drug was shown to be safe and to work against the virus. HIV cell entry is a three-step process. The virus must first attach to the

Follow Us

  • Facebook Page:
  • Twitter: zephyrfound
  • YouTube: zephyrfoundation

Controllers in Study

 Donation Thermometer
 Donation Thermometer
 Donation Thermometer

Our Goal:
December 30, 2009

Current Breakdown: 505 Elite Controllers 1009 Viremic Controllers 211 Other